Cell Rep: Chinese Academy of Sciences Liu Hongwei, Liu Shuangjiang team's latest research results: Reishi derivatives may be expected to help treat non-alcoholic fatty liver!

August 15, 2020 // -- In a recent study published in the international journal Cell Reports, scientists from the Institute of Microbiology of the Chinese Academy of Sciences and other institutions reported on the GMD, Ganoderma meroterpene derivatives The anti-non-alcoholic fatty liver disease (NAFLD) effect, the researchers said, GMD can increase the abundance of mycobacterium bacteria to activate the genus Bacillus anthropobacteria-folic acid-liver path, which in turn slows symptoms in patients with non-alcoholic fatty liver disease.
Photo Source: CC0 Public DomainNAFLD is one of the most common chronic liver diseases that is increasingly becoming a public health issue affecting the health of people around the world, but there is no effective drug approval for the treatment of this liver disease, and the prominent chemical diversity and biological activity of natural products and their derivatives make it a source and focus for potential drug development, such as Ganoderma Mushroom, which has been a traditional Chinese medicine for thousands of years.
Recently, researchers revealed the effects of GMD in slowing non-alcoholic fat degeneration in rats, saying that ingesting GMD increases lipid oxidation in the body, inhibits the synthesis of fat from new synthesis and the excretation of fat from the liver, and also inhibits endotoxemia, which, as an active preparation, seems unlikely to be absorbed by the body orally, so researchers do not yet know the specific molecular mechanisms by which GMD exerts effects.
In this study, researchers identified four groups of bacteria rich in GMD that can produce folic acid, namely, de solution, by conducting in vitro and in vivo experiments that showed that the intestinal bacteriocytes and folic acid-producing virulocytes that had been engineered to increase production may have been key factors in promoting the therapeutic effects of GMD on NAFLD. Bacteroides xylanisolvens, Polymorphic Bacteroides thetaiotaomicron, Monomorphic Bacteroids uniformis, and Bacteroides dorei, as well as the study's first reported folic acid production in these four gut bacillus groups.
the liver fatty degeneration of mice activated by the body's folic acid-mediated signaling path pathline can be slowed by oral decomposition of bacillus glycobacteria (one of the most promoted intestinal bacteriums in GMD), in order to confirm the key role of folic acid produced by the intestines in the development of NAFLD. By knocking out the folp gene in the folic acid biosynthesis pathway, the researchers aimed at removing the missing pyrethroid pyrethroid (BX-folP) in folic acid synthesis, and found that feeding mice with BX-folP may not be able to slow the performance of NAFLD disease in their bodies.
Finally, the researchers said that the study revealed the anti-NAFLD effects mediated by the Reishi derivative compound GMD, and identified a particularly useful intestinal anthropobacteria-folic acid-liver axis that could help develop new therapies for the treatment of NAFLD.
() Original source: Shanshan Qiao, Li Bao, Kai Wang, et al. Activation of a Specific Gut Bacteroides-Folate-Liver Axis Benefits for the People of The People of Nonalcoholic Hepatic Steatosis, Cell Reports (2020). DOI: 10.1016/j.celrep.2020.108005.